WO2009130479A3 - Virus - Google Patents

Virus Download PDF

Info

Publication number
WO2009130479A3
WO2009130479A3 PCT/GB2009/001056 GB2009001056W WO2009130479A3 WO 2009130479 A3 WO2009130479 A3 WO 2009130479A3 GB 2009001056 W GB2009001056 W GB 2009001056W WO 2009130479 A3 WO2009130479 A3 WO 2009130479A3
Authority
WO
WIPO (PCT)
Prior art keywords
virus
provides
attenuated virus
attenuated
Prior art date
Application number
PCT/GB2009/001056
Other languages
French (fr)
Other versions
WO2009130479A2 (en
Inventor
Leonard William Seymour
Ryan Cawood
Original Assignee
Isis Innovation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Innovation Limited filed Critical Isis Innovation Limited
Publication of WO2009130479A2 publication Critical patent/WO2009130479A2/en
Publication of WO2009130479A3 publication Critical patent/WO2009130479A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10061—Methods of inactivation or attenuation

Abstract

The invention provides an attenuated virus.
PCT/GB2009/001056 2008-04-23 2009-04-23 Virus WO2009130479A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0807424.7 2008-04-23
GB0807424A GB0807424D0 (en) 2008-04-23 2008-04-23 Virus

Publications (2)

Publication Number Publication Date
WO2009130479A2 WO2009130479A2 (en) 2009-10-29
WO2009130479A3 true WO2009130479A3 (en) 2009-12-17

Family

ID=39494125

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2009/001056 WO2009130479A2 (en) 2008-04-23 2009-04-23 Virus

Country Status (2)

Country Link
GB (1) GB0807424D0 (en)
WO (1) WO2009130479A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012009508A2 (en) * 2010-07-15 2012-01-19 Emory University Microrna compositions and methods related thereto
EP2450638A1 (en) 2010-09-03 2012-05-09 Jan Willem Driessen Bracket for heating installation
WO2012047109A2 (en) * 2010-10-08 2012-04-12 Orca Therapeutics B.V. Mirna and mirna inhibitors that modulate adenovirus replication and/or adenovirus induced cell death
WO2012051491A1 (en) * 2010-10-14 2012-04-19 The United States Of America, As Represented By The Secretary National Institutes Of Health Compositions and methods for controlling neurotropic viral pathogenesis by micro-rna targeting
IT1405997B1 (en) * 2010-10-28 2014-02-06 Università Degli Studi Di Bari METHOD AND KIT FOR DIAGNOSIS OF IGA NEPHROPATHY
EP2681309A4 (en) * 2011-03-01 2014-10-29 Scripps Research Inst Direct reprogramming of human fibroblasts to functional neurons under defined conditions
CN103866011B (en) * 2014-03-03 2016-04-13 吉林大学 The identification mmu-miR-712-3p of toxoplasma gondii infection can be detected
CN103866012B (en) * 2014-03-03 2016-04-13 吉林大学 The identification mmu-miR-217-5p of toxoplasma gondii infection can be detected
CN104974987B (en) * 2014-04-04 2018-06-19 宁夏医科大学 Purposes of the small molecule RNA-1247-5p as novel tumor treatment molecular target
CN103940998B (en) * 2014-05-04 2016-04-20 山东大学 The application of the early diagnosis marker that serum microRNA shifts as hepatocellular carcinoma
KR101670469B1 (en) * 2014-10-23 2016-10-28 고려대학교 산학협력단 Composition comprising microRNA for preventing or treating PCV2 infection
JP6620294B2 (en) * 2014-12-03 2019-12-18 公益財団法人ヒューマンサイエンス振興財団 Mumps virus attenuation method, mumps virus, and live vaccine
WO2018194089A1 (en) * 2017-04-19 2018-10-25 国立大学法人東京大学 Genetically engineered coxsackievirus, and pharmaceutical composition
AU2018306455A1 (en) 2017-07-26 2020-02-27 Virogin Biotech Canada Ltd Oncolytic viral vectors and uses thereof
CN108531485B (en) * 2018-04-14 2021-06-22 湖北省农业科学院畜牧兽医研究所 Application of pig miR-27b-3p as porcine reproductive and respiratory syndrome virus inhibitor
CN109609657B (en) * 2018-12-07 2022-04-01 湖北省农业科学院畜牧兽医研究所 Application of reagent for detecting miRNA-218-5p expression level in preparation of duck intestinal mucosa oxidative stress injury detection reagent
CN110564859B (en) * 2019-06-13 2022-06-24 中国农业科学院兰州兽医研究所 Marker and kit for fasciola hepatica infection detection
EP4170022A1 (en) * 2021-10-19 2023-04-26 Consejo Superior De Investigaciones Científicas Recombinant african swine fever virus and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006111512A1 (en) * 2005-04-19 2006-10-26 Basf Plant Science Gmbh Improved methods controlling gene expression
WO2008071959A1 (en) * 2006-12-12 2008-06-19 Oxford Biomedica (Uk) Limited Lentiviral vectors comprising micrornas
WO2008103755A1 (en) * 2007-02-20 2008-08-28 Mayo Foundation For Medical Education And Research Treating cancer with viral nucleic acid

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006111512A1 (en) * 2005-04-19 2006-10-26 Basf Plant Science Gmbh Improved methods controlling gene expression
WO2008071959A1 (en) * 2006-12-12 2008-06-19 Oxford Biomedica (Uk) Limited Lentiviral vectors comprising micrornas
WO2008103755A1 (en) * 2007-02-20 2008-08-28 Mayo Foundation For Medical Education And Research Treating cancer with viral nucleic acid

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BARNES DWIGHT ET AL: "Harnessing endogenous miRNAs to control virus tissue tropism as a strategy for developing attenuated virus vaccines.", CELL HOST & MICROBE 11 SEP 2008, vol. 4, no. 3, 11 September 2008 (2008-09-11), pages 239 - 248, XP002544788, ISSN: 1934-6069 *
BROWN BRIAN D ET AL: "Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 25, no. 12, 16 November 2007 (2007-11-16), pages 1457 - 1467, XP002471752, ISSN: 1087-0156 *
CAWOOD RYAN ET AL: "Use of tissue-specific microRNA to control pathology of wild-type adenovirus without attenuation of its ability to kill cancer cells.", PLOS PATHOGENS MAY 2009, vol. 5, no. 5, May 2009 (2009-05-01), pages e1000440, XP002544786, ISSN: 1553-7374 *
CHANG JINHONG ET AL: "miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1.", RNA BIOLOGY JUL 2004, vol. 1, no. 2, July 2004 (2004-07-01), pages 106 - 113, XP002544785, ISSN: 1555-8584 *
KELLY ELIZABETH J ET AL: "Engineering microRNA responsiveness to decrease virus pathogenicity.", NATURE MEDICINE NOV 2008, vol. 14, no. 11, November 2008 (2008-11-01), pages 1278 - 1283, XP002544787, ISSN: 1546-170X *
LAGOS-QUINTANA M ET AL: "Identification of Tissue-Specific MicroRNAs from Mouse", CURRENT BIOLOGY, CURRENT SCIENCE, GB, vol. 12, no. 9, 30 April 2002 (2002-04-30), pages 735 - 739, XP026073748, ISSN: 0960-9822, [retrieved on 20020430] *
TANG G: "siRNA and miRNA: an insight into RISCs", TRENDS IN BIOCHEMICAL SCIENCES, ELSEVIER, HAYWARDS, GB, vol. 30, no. 2, 1 February 2005 (2005-02-01), pages 106 - 114, XP004731285, ISSN: 0968-0004 *

Also Published As

Publication number Publication date
WO2009130479A2 (en) 2009-10-29
GB0807424D0 (en) 2008-05-28

Similar Documents

Publication Publication Date Title
WO2009130479A3 (en) Virus
WO2011142858A3 (en) Chlorotoxin variants, conjugates, and methods for their use
WO2011072099A3 (en) Compositions and methods comprising protease variants
WO2012061290A3 (en) Pesticidal compositions and processes related thereto
WO2008014008A3 (en) Compositions and methods for modulating angiogenesis
WO2008070269A3 (en) Methods, software and systems for imaging
WO2007130697A3 (en) Anti-ephb4 antibodies and methods using same
GB2477477A9 (en) Hob.
AP00226S1 (en) Impeller.
WO2007127506A8 (en) Anti-ephrinb2 antibodies and methods using same
WO2010005622A3 (en) Telescoping devices
WO2009039414A8 (en) Methods and compositions for detection of ehrlichia chaffeensis (vlpt)
WO2011050188A8 (en) Anti-hepsin antibodies and methods using same
WO2011117271A3 (en) Fungicidal mixtures based on azolopyrimidinylamines
WO2011014872A3 (en) Compositions and methods for diagnosing, treating or preventing neoplasias
AU2008100909A4 (en) The Challenge of ............
AU2008906062A0 (en) An improved M.V. 23-11-2008
GB0808063D0 (en) Versatile impellable protector (V.I.P)
GB0805811D0 (en) S.t.e.p.
GB0805810D0 (en) S.t.e.p.
AU2006903624A0 (en) B.b.e.
AP2011005663A0 (en) Electro-immunisation chamber.
WO2009069130A3 (en) New adjuvant
AU2008900849A0 (en) Compression chamber B.
AU2008905230A0 (en) iRoc (www.iroc.com.au)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09735155

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09735155

Country of ref document: EP

Kind code of ref document: A2